Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer

Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer

Several lines of preclinical evidence indicate that combining PI3K and CDK4/6 inhibitors may further enhance the efficacy of hormonal therapy by overcoming de novo and acquired resistance to PI3K and CDK4/6 blockade. We evaluated the combination of abemaciclib, letrozole and LY3023414 (an orally ava...

Full description

Bibliographic Details
Main Authors: Panagiotis A. Konstantinopoulos, Niya Xiong, Carolyn Krasner, Joyce F. Liu, Hannah Sawyer, Madeline Polak, Hope Needham, Megan Geddes, Lani Koppermann, Meghan Shea, Cesar Castro, Su-Chun Cheng, Ursula A. Matulonis, Elizabeth K. Lee
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:Gynecologic Oncology Reports
Subjects:
Abemaciclib
Aromatase inhibition
CDK4/6 inhibition
PI3K inhibition
LY3023414
Endometrial cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578924000274

Internet

http://www.sciencedirect.com/science/article/pii/S2352578924000274

Similar Items